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CONGENITAL HEART DISEASEFetal cardiac intervention: Improved results of fetal cardiac bypass
in immature fetuses using the TinyPump deviceVinod A. Sebastian, MD,a Giuseppe Ferro, MD,a Hiroshi Kagawa, MD, PhD,a Teimour Nasirov, MD,a
Katsuhide Maeda, MD, PhD,a William T. Ferrier, MS, DVM,b Setsuo Takatani, PhD, DMed,c
R. Kirk Riemer, PhD,a Frank L. Hanley, MD,a and V. Mohan Reddy, MDaFrom th
Stanf
and
Medi
and D
Disclosu
Abstrac
Exhib
Receive
public
Address
300 P
com).
0022-52
Copyrig
http://dx
1460Objective: Fetal cardiac surgery is a potential innovative treatment for certain congenital heart defects that have
significant mortality and morbidity in utero or after birth, but it has been limited by placental dysfunction after
fetal cardiac bypass. We have used the TinyPump device for fetal cardiac bypass in sheep fetuses at 90 to
110 days gestation.
Methods: Ten mixed-breed pregnant ewes were used over a period of 6 months, and 10 fetuses were placed on
bypass for 30 minutes. Five fetuses with a mean gestational age of 104 4.5 days and mean weight of 1.4 0.4
kg were placed on bypass using the TinyPump device, and 5 fetuses with a mean gestational age of 119  4.5
days and mean weight of 3.4  0.4 kg were placed on bypass using the roller head pump. The fetuses were
monitored for up to 3 hours after bypass or until earlier demise.
Results: Progressive respiratory and metabolic acidosis developed in all fetuses. The TinyPump group had
a lower gestational age and weight compared with the roller head pump group. However, the rate of postbypass
deterioration in the TinyPump group, as measured with blood gases, was noted to be significantly slower com-
pared with the roller head pump group.
Conclusions: We demonstrate the feasibility of the TinyPump device for fetal cardiac bypass in a fetal sheep
model. The TinyPump group showed improved results compared with the roller head group despite more imma-
ture fetuses. The TinyPump device seems to be a promising device for future studies of fetal cardiac bypass in
immature fetal sheep and in primates. (J Thorac Cardiovasc Surg 2013;145:1460-4)Fetal cardiac surgery is an exciting potential innovative ther-
apy for the treatment of complex cardiac anomalies that start
out as relatively simple lesions in early gestation. Fetal echo-
cardiography can permit the diagnosis of congenital heart de-
fects during early gestation. Some complex congenital
cardiac lesions are thought to be the result of relatively simple
primary lesions that progress because of altered intracardiac
blood flow patterns1 that may be altered with fetal therapy.
Most open fetal cardiac interventions will require some
formof fetal extracorporeal circulation (fetal cardiac bypass).
The feasibility of fetal cardiac bypass has been shown, and
the physiologic consequences of fetal cardiac bypass, includ-
ing severe placental dysfunction, have been described.2-9
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The Journal of Thoracic and Cardiovascular Surextracorporeal surfaces, priming substances, flow
characteristics, and fetal stress. Large cardiac bypass
circuits also require adult blood for priming, which has
a different oxygen affinity than fetal blood. We previously
showed that the use of the Hemopump (Modified model
of HP24 sternotomy pump; Johnson & Johnson
Interventional Systems, Rancho Cordova, Calif) to reduce
extracorporeal surface area and avoid external priming
substances leads to improved placental hemodynamics
after fetal cardiac bypass.10 The Hemopump currently is
not in production, and its minimal flow rate was too high
when used in primate fetuses and lamb fetuses weighing
less than 1500 g for fetal cardiac bypass.
The TinyPump device is a disposable centrifugal pump
that was developed at TokyoMedical and Dental University
in 2004.11 The TinyPump device comprises a console,
reusable motor driver, and disposable pump head easily
attached to and detached from the motor driver. Six pole
magnets are installed inside the impeller and radially
coupled to the outer driver magnets rotated by a direct
current motor. The impeller motor is suspended approxi-
mately 1 mm above the bottom surface of the housing by
a radial magnetic coupling force and further suspended
by a hydrodynamic bearing at the center of the impeller,
creating an effect similar to a noncontact suspension of
the impeller. A secondary flow inside the pump head is
designed to pass through between the impeller and thegery c June 2013
Sebastian et al Congenital Heart Disease
C
H
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possibly prevent thrombus formation inside the pump
head. The pump has 5 mL of priming volume including
the space inside the one-quarter inch inflow and outflow
ports. It weighs 150 g, including a reusable motor drive
and measures 493 20 mm. The impeller rotation supported
by the hydrodynamic bearing at the center can achieve
speeds between 500 and 5000 rpm. When used with one-
quarter inch inflow and outflow cannulae, the pump is
capable of providing flow of 0.1 to 4.0 L/min against
a head pressure of 100 mm Hg at pump speeds of 1500 to
4500 rpm.
In the fetal sheep model using the TinyPump device, we
have been able to obtain flow rates from 10 to 1000mL/min,
which has been adequate in our model and weight range.
This ability to provide a wide range of flows at both the
lower and upper ranges is crucial in advancing the fetal
cardiac bypass model to earlier stages of gestation and to
primate models that have smaller fetuses.
MATERIALS AND METHODS
Extracorporeal Circuits
TinyPump circuit. The circuit is shown in Figure 1. The circuit uses
the TinyPump device, which has inflow and outflow connectors for one-
quarter inch tubing and has a priming volume of 5 mL. The circuit has
a priming volume of 10 mL and 1 to 2 three-way stopcocks that can be
incorporated for deairing purposes. The circuit is primed with normosol
(Abbott Laboratories, Abbott Park, Ill), and the cannulae are backbled
with fetal blood. The small amount of normosol used for priming does
not seem to cause any significant hemodilution.
Conventional circuit. The conventional circuit consists of polyvi-
nyl one-quarter inch tubing, a collapsible neonatal extracorporeal mem-
brane oxygenation reservoir (mounted on plexiglass to prevent kinking),
a roller head pump (Cole-Parmer, Vernon Hills, Ill), and an in-line flow
probe (Transonic Systems, Inc, Ithaca, NY) (Figure 1). The circuit priming
volume varies from 75 to 100 mL and is primed with fresh adult sheep
venous blood.
Fetal Cardiac Bypass
The ewes were fasted overnight before the study and received cefazolin
intravenously (20 mg/kg) preoperatively and during the procedure. They
were premedicated with ketamine/valium intravenously. The ewe was
then placed supine on the operating table, intubated, and placed under
isoflurane maintenance anesthesia. The ewes were ventilated with a
Hallowell Veterinary Model 2000 ventilator (Hallowell Engineering &
Manufacturing Corp, Pittsfield, Mass), and capnography was used in addi-
tion to blood gases for assessment of ventilation. A central venous catheter
and arterial line were placed in the maternal jugular vein and carotid artery,
respectively, for monitoring. Maternal heart rate, blood pressure, central
venous pressure, and blood gases were monitored, and lactated Ringer’s
solution was given at 5 to 10 mL/kg/h. A midline laparotomy was per-
formed, and the uterus was exposed. The number and orientation of fetuses
were determined by palpation.
The fetal chest was palpated, and a hysterotomy was made directly over
the fetal chest, taking care to avoid the multiple cotyledons of the sheep
placenta. The fetal jugular vein and carotid artery were cannulated for
venous access and arterial blood pressure monitoring. Normosol infusion
at 1 mL/kg/min was started, and after the bypass protocol, dopamine at
5 mg/kg/min, epinephrine at 0.05 mg/kg/min, and calcium chloride at
20 mg/kg/hour were administered.The Journal of Thoracic and CarAmidline fetal sternotomy and pericardiotomywere performed, and the
heart was exposed. Themain pulmonary artery and superior vena cavawere
dissected. Purse-string sutures were placed in the main pulmonary artery
and superior vena cava for arterial and venous cannulation, respectively.
The fetus was anticoagulated with 300 U/kg of heparin sodium given
through the jugular central line. A 6F to 10F arterial cannula was used
for arterial cannulation. The right atrium was cannulated through the
superior vena cava because of the friable nature of fetal sheep atrium,
and 8F to 12F venous cannulae were used. In the TinyPump group, the
bypass circuit was primed with 10 mL of normosol and backbleeding of
fetal blood. In the conventional roller head group, the bypass circuit was
primed with adult blood. After deairing maneuvers were performed,
normothermic beating heart cardiac bypass was performed for 30 minutes
using the placenta as the sole oxygenator.
Pump flows were maintained at the maximum achievable flow in any
given fetus with an intention to provide at least 200 mL/kg/min of flow.
This is based on previous research showing that high flows are required
in fetal cardiac bypass when the placenta is used as the oxygenator.12,13
Pump flows were continuously monitored with the in-line flow probe.
After bypass discontinuation, infusion of dopamine at 5 mg/kg/min, epi-
nephrine at 0.05 mg/kg/min, and calcium chloride at 20 mg/kg/hour was
initiated. The fetus was monitored for up to 180 minutes or until earlier
demise. All baseline maternal and fetal hemodynamic data (maternal
and fetal heart rates, maternal and fetal central venous pressures, maternal
and fetal arterial pressures) were continuously recorded. Baseline mater-
nal and fetal blood gases were measured. Fetal blood gases were moni-
tored every 15 minutes during bypass and every 30 minutes in the
postbypass period. After completion of the study, the ewes and fetuses
were euthanized. The dead fetuses were delivered through the hyster-
otomy, towel-dried, and weighed.
All animals received humane care in compliance with the 1996 Guide
for the Care and Use of Laboratory Animals, recommended by the US
National Institutes of Health. The experimental protocol was approved
by the Institutional Animal Care and Use Committees at Stanford and at
the University of California, Davis.
Data Acquisition
Fetal and maternal systemic arterial pressures and fetal and maternal
central venous pressures were measured using Statham P23Db pressure
transducers (Statham Instruments, Inc, Hato Rey, Puerto Rico). Mean
pressures were obtained by electric integration. Heart rate was measured
by a cardiotachometer triggered from the phasic systemic arterial pressure
pulsewave. All flowsweremeasured on an ultrasonic flowmeter (Transonic
Systems Inc). Fetal and maternal blood gases were measured using an ABL
800 blood gas analyzer (Radiometer America, Westlake, Ohio).
RESULTS
Ten mixed-breed pregnant ewes were used over a period
of 6 months, and 10 fetuses were placed on bypass for
30 minutes. Five fetuses with a mean gestational age of
104  4.5 days and mean weight of 1.4  0.4 kg were
placed on bypass using the TinyPump device, and 5 fetuses
with a mean gestational age of 119  4.5 days and a mean
weight of 3.4  0.4 kg were placed on bypass using the
roller head pump. All fetuses developed progressive respi-
ratory and metabolic acidosis. However, the rate of postby-
pass deterioration in the TinyPump group, as measured with
blood gases, was noted to be significantly slower compared
with the roller head pump group.
The mean gestational age, mean fetal weight, arterial
blood gas data, and peak flow rate obtained in the TinyPumpdiovascular Surgery c Volume 145, Number 6 1461
FIGURE 2. Comparison between gestational age and body weight of the
roller head pump group versus the TinyPump group showed younger
gestational age and lower body weight in the TinyPump group: gestational
age 119 days versus 104  4.5 days (n ¼ 5, P ¼ .04) and body weight 3.4
kg versus 1.4  0.4 kg (n ¼ 5, P ¼ .008). *Statistically significant differ-
ence in gestational age and body weight. RP, Roller pump; TP, TinyPump.
FIGURE 1. TinyPump circuit comprising the TinyPump (A), 3-way stop
cock for deairing (B), and flow probe (C). Priming volume of circuit is
10 mL. Conventional fetal cardiac bypass circuit comprising venous reser-
voir (D), roller head pump (E), and flow probe (F). Priming volume of the
circuit varies from 75 to 100 mL.
Congenital Heart Disease Sebastian et al
C
H
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Student t test. The roller head pump group of fetuses had
a higher gestational age and weight compared with the
TinyPump fetuses (Figure 2). The roller head group had
a mean gestational age of 119  4.5 days (n ¼ 5,
P ¼ .04) versus 104  4.5 days in the TinyPump group.
The mean weight of the roller head pump fetuses was 3.4
 0.4 kg versus 1.4 0.4 kg in the TinyPump group (n¼ 5,
P¼ .008). Despite this inherent disadvantage in gestational
age and weight, the TinyPump group had more favorable
blood gas results than the roller head pump group.
Arterial Blood Gases
Table 1 shows the blood gases obtained in the 2 groups of
fetuses that had the roller head pump and TinyPump used
for fetal cardiac bypass. We found statistically significant
improvement in carbon dioxide tension and lactate levels
in the TinyPump group (Figure 3 and Table 1).
Peak Flow Rate Obtained
We noticed a significantly higher peak flow rate in the
TinyPump group compared with the roller head group
(Figure 4). The peak flow rate obtained in the TinyPump
group was 236  19 mL/kg/min (n ¼ 5) versus 124 
19 mL/kg/min (n ¼ 5) (P ¼ .003).
DISCUSSION
The flow-related theory of cardiac morphogenesis and
the earlier prenatal echocardiographic detection of congen-
ital cardiac disease suggest that in utero repair of certain
congenital cardiac diseases, such as pulmonary atresia
with intact ventricular septum, critical aortic stenosis,
tetralogy with absent pulmonary valve syndrome, and1462 The Journal of Thoracic and Cardiovascular Sursevere Ebstein’s anomaly, may be highly advantageous.
Most of these interventions will require the use of fetal
cardiac bypass, which has the limitation of producing
placental dysfunction.
The clinical application of fetal noncardiac surgery and
catheter-based cardiac intervention has been carried outgery c June 2013
TABLE 1. Blood gas values in TinyPump and roller head pump groups at 30, 60, and 90 minutes after fetal cardiac bypass
Type of pump 30 min after bypass 60 min after bypass 90 min after bypass
Mean pH Roller head pump 7.12  0.04 (n ¼ 5) 7.02  0.06 (n ¼ 5) 7.04  0.09 (n ¼ 3)
TinyPump 7.18  0.04 (n ¼ 5) (P ¼ .8) 7.15  0.07 (n ¼ 4) (P ¼ .9) 7.07  0.08 (n ¼ 4) (P ¼ .5)
Mean PO2 Roller head pump 21.5  4 (n ¼ 5) 21.6  3.9 (n ¼ 5) 24.8  6 (n ¼ 3)
TinyPump 26.8  4 (n ¼ 5) (P ¼ .8) 18.7  4.3 (n ¼ 4) (P ¼ .3) 17.5  5.2 (n ¼ 4) (P ¼ .2)
Mean PCO2 Roller head pump 89.1  4.8 (n ¼ 5) 109.6  11 (n ¼ 5) 114.23  15.5 (n ¼ 3)
TinyPump 57.8  4.8 (n ¼ 5) (P ¼ .0009) 67.9  12.3 (n ¼ 4) (P ¼ .02) 76.9  13.4 (n ¼ 4) (P ¼ .009)
Mean lactate Roller head pump 8.2  1.16 (n ¼ 5) 10.5  1.1 (n ¼ 5) 11.4  1.3 (n ¼ 3)
TinyPump 3.7  1.16 (n ¼ 5) (P ¼ .01) 3.9  1.25 (n ¼ 4) (P ¼ .003) 5.4  1.16 (n ¼ 4) (P ¼ .009)
Statistically significant data are in bold. Po2, Oxygen tension; Pco2, carbon dioxide tension.
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earlier. This corresponds to 90 to 110 days sheep gesta-
tion.14 The use of sheep fetuses at earlier gestation is
more relevant to current clinical attempts at fetal therapy.
Immature fetuses may have different uteroplacental hemo-
dynamics and seems to be more susceptible to placental
dysfunction than more mature fetuses. Placental dysfunc-
tion continued to be a major obstacle in these immature
fetuses, and although the rate of decline of placental dys-
function was noted to be slower than in mature fetuses
undergoing bypass with the roller head pump, we generally
could not prevent the ultimate deterioration of placentalFIGURE 3. Comparison between carbon dioxide tension (PCO2) and
lactate in the roller head pump and TinyPump groups showed significantly
higher PCO2 and lactate values in the roller head pump group at 30, 60, and
90 minutes after fetal cardiac bypass. *Statistically significant difference in
PCO2 and lactate levels. Pco2, Carbon dioxide tension; RP, roller pump; TP,
TinyPump.
The Journal of Thoracic and Carfunction. Technical limitations in terms of tissue fragility
and size of cannulae to be used are even more relevant in
this gestational age than in the mature fetus. Even small
amounts of blood loss during cannulation may result in
significantly lower hematocrit, and fluid resuscitation leads
to hemodilution more easily than in the mature fetus. All
these issues require further work to elucidate techniques
of fetal cardiac bypass at this gestational age.
These immature sheep fetuses are closer in size to pri-
mate fetuses, although primate fetal tissue may have higher
tensile strength than sheep fetuses. Pump flow rate during
bypass is also a critical parameter for maintenance of fetal
gas exchange. In our previous primate experiments using
the roller head pump, we had to infuse crystalloid at
50 mL/kg/min to maintain an adequate bypass flow (maxi-
mum flow of 176  70 mL/kg/min) and hemodynamics.15
This was done using a 10F atrial venous cannula and 14- or
16-gauge arterial cannula. In the present study and inFIGURE 4. Comparison between peak flow rate in the roller head pump
and TinyPump groups showed a higher peak flow rate in the TinyPump
group: 236mL/kg/minversus 124 19mL/kg/min (n¼ 5,P¼ .003). *Sta-
tistically significant difference in peak flow rate. RP, Roller pump; TP, Ti-
nyPump.
diovascular Surgery c Volume 145, Number 6 1463
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not require these extremely high amounts of intravenous
fluid resuscitation. We have followed the guidelines recom-
mended by Baker and colleagues16 for intravenous fluid re-
suscitation at 1 mL/kg/h. Peak flows of 236 mL/kg/min
were obtained using 10F to 12F venous cannulae (inserted
through the superior vena cava) and 6F to 8F arterial can-
nula. The techniques used in fetal cardiac bypass in these
immature sheep fetuses are more applicable to the primate
model, which is an important step before any human appli-
cation of fetal cardiac bypass. We anticipate that in primate
models permitting direct atrial cannulation, the peak flows
obtained during bypass will be even higher.
Our previous circuit with the Hemopump did not have
any means to protect against air embolism. In the present
circuit, we did not incorporate any bubble traps or air bubble
detectors, but we did place 3 way stopcocks on both the
venous and arterial side for manual deairing.
We have previously performed studies2-4 to block
placental dysfunction in more mature fetuses. We are
continuing to incorporate this pharmacologic blockage in
the new TinyPump model.CONCLUSIONS
We report the use of the TinyPump for fetal cardiac
bypass in a fetal sheep model of 105 days gestational age.
The pump showed improved results over the roller head
group with improved blood gas parameters despite more
immature fetuses in the TinyPump group. The pump has
low priming volumes and a wide range of flow rates that
can be easily adjusted. Both these factors make it a pro-
mising device for future studies of fetal cardiac bypass in
immature fetal sheep and in primates, both of which are
crucial before this therapy can be applied to humans.1464 The Journal of Thoracic and Cardiovascular SurReferences
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